OPB 111077

Drug Profile

OPB 111077

Alternative Names: OPB-111077

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical
  • Developer Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Acute myeloid leukaemia
  • No development reported Hepatocellular carcinoma

Most Recent Events

  • 19 Jul 2017 Otsuka America Pharmaceutical terminates a phase I trial due to noncompliance to the DSMP in Acute myeloid leukaemia (Combination therapy, Newly diagnosed, Second-line therapy) in USA (PO) (NCT03063944)
  • 13 Jun 2017 Otsuka Pharmaceutical plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in Spain (PO) (NCT03197714)
  • 22 May 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in Singapore (PO) (NCT03158324)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top